Skip to main navigation
logo

Investor Relations

  • Overview
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
  • News & Events
    • News Releases
    • Investor Calendar
    • Presentations & Publications
  • Financial Information
    • SEC Filings
    • financial and regulatory reports
    • shareholder circular
  • Corporate Governance
    • Governance Overview
    • Leadership
    • Board of Directors
  • Shareholder Services
    • Investor FAQs
    • Email Alerts
    • Contact IR

Presentations & Publications

Corporate Presentations

corporate presentation
Apr 18, 2022

Data & Congress Presentations

Early Results of Intratumoral INT230-6 Alone or in Combination with Ipilimumab in Subjects with Advanced Sarcomas
Source
Presented at ASCO 2021
A Phase 1/2 study of Intratumoral INT230-6 Alone (IT-01) or in Combination with Pembrolizumab [KEYNOTE-A10] in Adult Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors Refractory to Therapy
Source
Presented at ASCO 2021

Publications

PLGA Nanoparticles Co-encapsulating NY-ESO-1Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses
Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models
Co-delivery of PLGA Encapsulated Invariant NKT Cell Agonist with Antigenic Protein Induce Strong T Cell-Mediated Antitumor Immune Responses

Featured Pages

Stock Information
Financial Information
Contact IR
FAQs

Investor Tools

  • Print Page
  • RSS Feeds
  • Email Page
  • Email Alerts

Copyright © All rights reserved Portage Biotech

Legal Links

Terms of Use  Privacy policy   Disclaimer

  • Facebook
  • Twitter
  • LinkedIn
  • Google+